Cambridge Healthtech Institute’s 6^th Annual

CAR Ts, TCRs and TILs

Latest Innovations and Developments in Adoptive Cell Therapy

April 10-11, 2019

Novel gene editing technologies and a greater understanding of cancer biology could unleash the full power of CAR T in both blood and solid tumors. But which therapies will succeed?

Cambridge Healthtech Institute’s Sixth Annual CAR Ts, TCRs and TILs conference focuses on the latest research, protein engineering and clinical strategies driving the development of adoptive cell therapies across a wide range of indications. Clinical progress with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), Tumor Infiltrating Lymphocytes (TIL), and NK cells will be addressed as well as new strategies for commercialization will be reviewed.

Preliminary Agenda

LATEST DEVELOPMENTS IN CAR T

Mechanisms of CAR Treatment Success and Failure Based on Clinical Experience in Lymphoma and Leukemia

Adrian Bot, PhD, Vice President, Translational Sciences, Kite Pharma, a Gilead Company

Resistance to CART19 Therapy: Mechanisms and Novel Therapeutic Strategies

Marco Ruella, MD, Clinical Instructor, Associate Director, Dr. June’s Laboratory, Center for Cellular Immunotherapies (CCI), Perelman School of Medicine, University of Pennsylvania

Novel Targets and Technologies for CAR T Cells in Multiple Myeloma and Acute Myeloid Leukemia

Michael Hudecek, PhD, Associate Professor, University of Hudecek

Allogeneic CAR T: The Next Revolution in Cell Therapy

Barbra Sasu, PhD., CSO, Allogene

Presentation to be Confirmed

Stefan Scherer, MD, PhD., Senior Vice President, Clinical Development and Deputy Chief Medical Officer, Cellectis

Combining Innate and Adaptive Immunity: NK Receptors for CAR T Cell Therapy

David Gilham, PhD., VP, Research, Celyad

Targeting TCR-β Constant Domain for Immunotherapy of T-cell Malignancies

Shimobi Onuoha, PhD., Head, Protein Engineering, Autolus

TCR, TILs

Expanding The Tractable Tumor Target Universe with T Cells Carrying Engineered TCRs

Iulia Diaconu, PhD., Associate Director, Immunotherapy, Bluebird Bio

Gene Editing of Stem Cells for Universal SPEAR T-Cell Therapy

Joanna Brewer, PhD., Vice President, Platform Sciences, AdaptImmune

TIL Therapy for Solid Tumors

Chantale Bernatchez, PhD., Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Advancements in Tumor Infiltrating Lymphocytes in Treatment of Solid Tumors

Maria Fardis, PhD, CEO, Iovance

Luncheon Presentation: Genetically-Modified Cell Lines for Immuno-Oncology Cell-Based Assay Development

Speaker to be Announced, MilliporeSigma

Presentation to be Announced

* The program is subject to change without notice, due to unforeseen reason.